Mar. 26 at 8:02 AM
$PYXS $MLTX $DRTS $RVMD
Stop focusing on the immediate milestones and look at the massive valuation gaps in these four biotech platforms.
$PYXS Major institutional confidence here. Jefferies recently set a
$8.00 price target while it’s trading closer to
$1.42. This is a long-term play on a mature platform.
$MLTX This is a powerhouse in the making. Their Phase 2 success in axSpA 'ith a BLA submission for HS planned for 2H 2026, the gap between the current price and fair value is wide.
$DRTS The skin cancer trial is a huge de-risking event. The true platform’s success in internal organs. With an 81% Disease Control Rate in Pancreatic cancer and ongoing U.S. Brain trials, this is a multi-billion dollar oncology play.
$RVMD Analysts have estimates as high as
$170, yet it’s trading around
$95. Their RAS(ON) pipeline is becoming the gold standard for targeted oncology in lung and colorectal cancers.
The biggest gains in biotech come for those who stay patient
